Anavex Life Sciences (AVXL) Tmuɣli n wazal
Ṛṛbem n lḥedd$2.38Yettwalemmaḍ 25 Sep 2026 19:59 UTC
Beddel+1.71%
Asnulfu n AI: AVXL
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
Anavex Life Sciences Corp. operates as a biopharmaceutical company that leverages precision genetic medicine to treat severe and debilitating neurological disorders, with a particular focus on rare diseases lacking available therapies and on treating high-risk central nervous system patient populations. Anavex Life Sciences serves customers worldwide.
